BiotechTube

ALN-TTRSC04 + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Transthyretin-Mediated Amyloidosis

Conditions

Transthyretin-Mediated Amyloidosis

Trial Timeline

Jan 16, 2023 → Sep 30, 2025

NCT ID
NCT05661916

About ALN-TTRSC04 + Placebo

ALN-TTRSC04 + Placebo is a phase 1 stage product being developed by Alnylam Pharmaceuticals for Transthyretin-Mediated Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05661916. Target conditions include Transthyretin-Mediated Amyloidosis.

What happened to similar drugs?

0 of 5 similar drugs in Transthyretin-Mediated Amyloidosis were approved

Approved (0) Terminated (0) Active (5)
🔄Eplontersen + PlaceboAstraZenecaPhase 3
🔄EplontersenAstraZenecaPhase 3
🔄Nucresiran + VutrisiranAlnylam PharmaceuticalsPhase 3
🔄EplontersenIonis PharmaceuticalsPhase 3
🔄Inotersen + EplontersenIonis PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05661916Phase 1Completed

Competing Products

9 competing products in Transthyretin-Mediated Amyloidosis

See all competitors
ProductCompanyStageHype Score
Eplontersen Solution for InjectionAstraZenecaPhase 1
29
Eplontersen + PlaceboAstraZenecaPhase 3
44
EplontersenAstraZenecaPhase 3
47
PatisiranAlnylam PharmaceuticalsPre-clinical
23
PatisiranAlnylam PharmaceuticalsPre-clinical
23
ALN-TTRSC02 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
26
Nucresiran + VutrisiranAlnylam PharmaceuticalsPhase 3
44
EplontersenIonis PharmaceuticalsPhase 3
41
Inotersen + EplontersenIonis PharmaceuticalsPhase 3
37